New Zealand

Medsafe is the primary regulatory authority responsible for the approval and oversight of medicines, medical devices, diagnostics, and related health products in New Zealand. The principal governing legislation is the Medicines Act 1981 and the Medicines Regulations 1984, supplemented by the Medical Devices (Conformity Assessment) Regulations 2019 and associated standards. Pharmaceutical products require formal consent to market, assessed through Medsafe's New Medicine Application (NMA) or Changed Medicine Notification (CMN) pathways, depending on the nature of the product. Medical devices are regulated under a conformity assessment framework aligned with international standards, with higher-risk devices requiring third-party certification from a Conformity Assessment Body (CAB) and Medsafe registration. Digital health products are subject to evolving guidance, and those meeting the definition of a medical device are regulated accordingly.

New Zealand accepts applications prepared in the International Council for Harmonisation (ICH) Common Technical Document (CTD) format, streamlining submissions for sponsors already engaged in major international markets. A local New Zealand agent or sponsor is required for all market authorisation applications, and sponsors must maintain ongoing pharmacovigilance obligations post-approval. Medsafe operates an established Provisional Consent pathway for medicines addressing unmet clinical needs, and actively participates in the Australia-New Zealand Therapeutic Products Agency (ANZTPA) initiative, a long-standing bilateral effort to establish a joint regulatory framework with Australia's Therapeutic Goods Administration (TGA). While ANZTPA has not yet been fully implemented, New Zealand increasingly aligns its regulatory guidance and reform agenda with TGA standards, and recognition of Australian TGA approvals can facilitate expedited pathways in certain circumstances.

Public procurement of health products in New Zealand is managed primarily at the national level through the Ministry of Health (Te Whatu Ora - Health New Zealand since the 2022 health system reforms), which centralised procurement functions previously distributed across 20 District Health Boards (DHBs). The Pharmaceutical Management Agency (PHARMAC) plays a uniquely powerful role in the New Zealand public health system, acting as the sole national buyer of publicly funded pharmaceuticals, vaccines, and an expanding range of medical devices. PHARMAC operates a rigorous health technology assessment (HTA) process, evaluating clinical evidence and cost-effectiveness before listing products on the Pharmaceutical Schedule or the Hospital Medicines List. Listing decisions are competitive, with PHARMAC negotiating directly with suppliers and frequently using sole-supply contracts and reference pricing to control expenditure. Medical devices and diagnostics procured outside PHARMAC's remit are typically managed through Health New Zealand's national procurement teams or by individual hospital networks using panel contracts and open tender processes governed by the Government Rules of Sourcing.

New Zealand does not rely significantly on donor-funded procurement channels such as UNICEF Supply Division, the Global Fund, USAID, or Gavi, as it is a high-income country with a self-funded public health system. The private healthcare sector, though smaller than the public system, procures health products independently through distributors and direct supplier agreements, and is not subject to PHARMAC listing requirements. There is no formal local manufacturing preference policy in New Zealand, and the market is largely import-dependent for pharmaceuticals and medical devices. However, Health New Zealand and PHARMAC have signalled increased interest in supply chain resilience and may give consideration to supply security factors in future procurement decisions. Companies entering the New Zealand market should prioritise PHARMAC engagement early, as Schedule listing is effectively the gateway to public sector sales volume.